Bluejay Diagnostics, Inc. (BJDX) NASDAQ
4.25
-0.095(-2.19%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.25
-0.095(-2.19%)
Currency In USD
| Previous Close | 4.34 |
| Open | 3.82 |
| Day High | 4.27 |
| Day Low | 3.75 |
| 52-Week High | 16.68 |
| 52-Week Low | 1.62 |
| Volume | 669,235.89 |
| Average Volume | 1.26M |
| Market Cap | 1.93M |
| PE | -1.14 |
| EPS | -3.74 |
| Moving Average 50 Days | 1.95 |
| Moving Average 200 Days | 4.2 |
| Change | -0.1 |
Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook
GlobeNewswire Inc.
Mar 06, 2026 11:30 AM GMT
ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in critical care settings, today p
Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised
GlobeNewswire Inc.
Feb 20, 2026 11:30 AM GMT
ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, an
Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026
GlobeNewswire Inc.
Feb 17, 2026 11:30 AM GMT
ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made substantial progress in advancing manufacturi